Unraveling the Interaction of Aspirin, Ticagrelor, and Rosuvastatin on the Progression of Atherosclerosis and Inflammation in Diabetic Mice

被引:13
|
作者
Ye, Yumei [1 ]
Nylander, Sven [2 ]
Birnbaum, Yochai [3 ]
机构
[1] Univ Texas Med Branch, Dept Biochem & Mol Biol, 301 Univ Blvd, Galveston, TX 77555 USA
[2] AstraZeneca R&D, Molndal, Sweden
[3] Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA
关键词
Aspirin; Statin; Ticagrelor; Clopidogrel; Adenosine; Atherosclerosis; Inflammation; ISCHEMIA-REPERFUSION INJURY; NITRIC-OXIDE SYNTHASE; LOW-DOSE ASPIRIN; RECEPTOR-DEFICIENT MICE; CYTOKINE-CHEMOKINE AXIS; MYOCARDIAL-INFARCTION; INDUCED CARDIOPROTECTION; NEUTROPHIL RESPONSES; ANTIPLATELET THERAPY; 15-EPI-LIPOXIN A(4);
D O I
10.1007/s10557-017-6763-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We explored the effects of rosuvastatin, aspirin, ticagrelor, and clopidogrel, alone or in combinations on the progression of atherosclerosis and inflammasome activation in diabetic mice. Statins and ticagrelor increase the production of 15-epi-lipoxin A(4) via cyclooxygenase-2. Aspirin alone increases 15-epi-lipoxin A(4), but when combined with statins, cyclooxygenase-2 is completely blocked. ApoE(-/-)/db(+)/db(+) double-knockout mice received rosuvastatin (5 mg/kg/day), aspirin (25 mg/kg/day), ticagrelor (300 mg/kg/day), clopidogrel (75 mg/kg/day), or their combination for 14 weeks. Serum 15-epi-lipoxin A(4) levels and aortic wall cholesterol content, IL-1 beta, IL-6, and TNF-alpha levels, and plaque area were assessed. Aspirin, ticagrelor, and rosuvastatin increased 15-epi-lipoxin A(4) levels. The combination of rosuvastatin + ticagrelor provided an additive effect. Aspirin attenuated the effect of both ticagrelor and rosuvastatin. Aspirin, ticagrelor, and rosuvastatin reduced the area of the atherosclerotic plaque. The combination of ticagrelor + rosuvastatin provided additive effects. There was a negative interaction when aspirin was combined with ticagrelor or rosuvastatin. Aspirin, ticagrelor, and rosuvastatin decreased serum IL-1 beta and IL-6 levels. There was no interaction between aspirin and ticagrelor or aspirin and rosuvastatin, whereas combining rosuvastatin and ticagrelor provided an additive effect. Aspirin, ticagrelor, and rosuvastatin all decreased TNF-alpha levels. Aspirin attenuated the effect of both ticagrelor and rosuvastatin, and there was no additive effect of combining ticagrelor + rosuvastatin. We found an intricate interaction between aspirin, ticagrelor, and rosuvastatin, as aspirin reduced both ticagrelor and rosuvastatin ability to ameliorate inflammation and atherosclerosis. In contrast, we found additive effects when ticagrelor and rosuvastatin were combined.
引用
收藏
页码:489 / 500
页数:12
相关论文
共 50 条
  • [1] Unraveling the Interaction of Aspirin, Ticagrelor, and Rosuvastatin on the Progression of Atherosclerosis and Inflammation in Diabetic Mice
    Yumei Ye
    Sven Nylander
    Yochai Birnbaum
    Cardiovascular Drugs and Therapy, 2017, 31 : 489 - 500
  • [2] PKCβ modulates accelerated initiation and progression of atherosclerosis in diabetic mice
    Harja, Evis
    Zou, Yu-Shan
    Lu, Yan
    Hudson, Barry I.
    Chang, Jong Sun
    Coku, Jorida
    Leitges, Michael
    Schmidt, Ann Marie
    Yan, Shi-Fang
    CIRCULATION, 2006, 114 (18) : 77 - 77
  • [3] Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
    Νarjes Nasiri-Ansari
    Georgios K. Dimitriadis
    Georgios Agrogiannis
    Despoina Perrea
    Ioannis D. Kostakis
    Gregory Kaltsas
    Athanasios G. Papavassiliou
    Harpal S. Randeva
    Eva Kassi
    Cardiovascular Diabetology, 17
  • [4] Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
    Nasiri-Ansari, Narjes
    Dimitriadis, Georgios K.
    Agrogiannis, Georgios
    Perrea, Despoina
    Kostakis, Ioannis D.
    Kaltsas, Gregory
    Papavassiliou, Athanasios G.
    Randeva, Harpal S.
    Kassi, Eva
    CARDIOVASCULAR DIABETOLOGY, 2018, 17
  • [5] Empagliflozin Suppresses the Progression of Atherosclerosis in Diabetic apoE-Deficient Mice
    Murakami, Saiko
    Matsumura, Takeshi
    Senokuchi, Takafumi
    Ishii, Norio
    Fukuda, Kazuki
    Nishida, Shuhei
    Kondo, Tatsuya
    Araki, Eiichi
    DIABETES, 2017, 66 : A51 - A51
  • [6] Rosuvastatin Inhibits MMP-2 Expression and Limits the Progression of Atherosclerosis in LDLR-deficient Mice
    Guo, Hangyuan
    Shi, Yafei
    Liu, Longbin
    Sun, Aijing
    Xu, Fukang
    Chi, Jufang
    ARCHIVES OF MEDICAL RESEARCH, 2009, 40 (05) : 345 - 351
  • [7] Rosuvastatin inhibits MMP-2 expression and improves the progression of atherosclerosis in LDLR-deficient mice
    Sun, Yong
    Guo, Hangyuan
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2009, 137 : S2 - S3
  • [8] PKC Promotes Vascular Inflammation and Acceleration of Atherosclerosis in Diabetic ApoE Null Mice
    Kong, Linghua
    Shen, Xiaoping
    Lin, Lili
    Leitges, Michael
    Rosario, Rosa
    Zou, Yu Shan
    Yan, Shi Fang
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2013, 33 (08) : 1779 - 1787
  • [9] Diabetic plaque inflammation and neovascularization are associated with increased reparative collagen content: Implications for plaque progression in diabetic atherosclerosis
    Purushothaman, KR
    Fuster, V
    Sirol, M
    O'Connor, WN
    Sharma, SK
    Hutter, R
    Moreno, PR
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (04) : 295A - 295A
  • [10] Tofogliflozin Suppresses the Progression of Atherosclerosis and Reduces Inflammation in Macrophages of STZ-Diabetic ApoE KO Mice due to Improvement of Glucose Tolerance
    Iwamoto, Masahiko
    Kubota, Naoto
    Kubota, Tetsuya
    Sakurai, Yoshitaka
    Wada, Nobuhiro
    Takamoto, Iseki
    Shioda, Seiji
    Kadowaki, Takashi
    DIABETES, 2018, 67